Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PowerMiT

Financiado

Leveraging the impact of gut microbes to advance the efficacy of CAR-T cell immu...

T cell therapy with chimeric antigen receptor (CAR)-T cells is a curative-intent, transformative treatment aimed to boost antitumor abilities of host T cells against refractory/relapsed B cell malignancies and, recently, against r... ver más

28/02/2029

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-05

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

2.00M€ | Lider

Proyectos interesantes

VACCIBIOME Cancer Vaccines and Gut Microbiome a rational approach to o... 2M€ Cerrado

CAR-TIME Drivers and Brakes of CAR T Cell Efficacy Determined by the... 1M€ Cerrado

MICROBOTS MICROBOTS – Unravel the power of MICRObial metaBOliTeS to pr... 2M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

PID2019-109546RA-I00 CELULAS T GENETICAMENTE MODIFICADAS PARA EXPRESAR RECEPTORES... 163K€ Cerrado

MOTM Metabolic optimisation of intra-tumoral T cell motility 212K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 60 meses Fecha Inicio: 2024-02-05
Fecha Fin: 2029-02-28

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto T cell therapy with chimeric antigen receptor (CAR)-T cells is a curative-intent, transformative treatment aimed to boost antitumor abilities of host T cells against refractory/relapsed B cell malignancies and, recently, against refractory/relapsed myeloma. Major challenges of current CAR-T cell immunotherapies are the loss of long-term efficacy, the occurrence of toxicities including infections, and a lack of personalized patient strategies including biomarkers for response prediction and interventions to enhance CAR-T cell efficacy. This proposal builds on our first evidence for a major role of the gut microbiome in CAR-T cell therapy, and addresses these challenges by presenting a translational research strategy aimed to dissect and leverage the impact of gut microbes in its antitumor efficacy. In Aim 1, we will investigate the hypothesis that gut and intratumoral microbiome configurations and its metabolites are associated with clinical response of CD19-CAR-T cells in lymphoma, with immunophenotypes of these engineered T cells and the tumor immune microenvironment. We will examine the effects of nutrition and antimicrobial drugs on microbiome features to identify potential mechanisms and therapeutic levers. In Aim 2, we will address the biology of microbiome-CAR-T cell interactions through experimental gut microbiome modulations, and humanizing mice with patient-derived microbial ecologies and individual species and strains in preclinical research models. In Aim 3, we will assess potential therapeutic interventions to increase CAR-T efficacy by investigating the action of microbiome-derived metabolites on CAR-T cells and studying phage- and diet-based interventions to mitigate antibiotic-induced gut microbiome dysbiosis. Characterising the function of the microbiome and its products in CAR-T immunotherapy harbours an enormous potential to improve current and future T cell transfer therapies for numerous patients suffering from cancer.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores